Table 2.

Table of summary statements from each section.

Target	Recommendations
VEGFR	Anti-VEGF therapies are most effective against highly vascularized STS and have moderate activity in LMS.
PDGFR	Aside from DFSP, the lack of correlative PDGF-related analyses in these trials do not allow for definitive conclusions to be made about the role of anti-PDGF activity in STS patients.
IFGR1	Patients with adipocytic sarcoma may benefit from treatment with single agent cixutumumab.
FGFR	Appears promising particularly in AS however there are no FGFR only directed treatments so extrapolation of clinical benefit due to this pathway specifically must be made carefully.
HDAC	No data to support single agent usage. Potential use in combination with other agents as an anti-autophagy modality.
mTOR	Single-agent mTOR inhibition shows a very modest PFS benefit but no survival advantage.
MDM2	Too soon to tell; may have utility in liposarcoma.
CDK / CHK1	Too soon to tell; potential therapeutic role in patients with CDK- amplified liposarcoma.
MEK	Too soon to tell; may have utility in LMS and in sarcomas with NF1 deletion.
AURKA	Too soon to tell; may have utility in angiosarcoma.